Tulobuterol hydrochloride

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C12H18ClNO.ClH
Molecular Weight	264.191
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1

InChI

InChIKey=RSLNRVYIRDVHLY-UHFFFAOYSA-N

InChI=1S/C12H18ClNO.ClH/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13;/h4-7,11,14-15H,8H2,1-3H3;1H

HIDE SMILES / InChI

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078
Curator's Comment: description was created based on several sources, including: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf

Tulobuterol is a long-acting beta2-adrenergic receptor agonist. Tulobuterol has almost no effects on blood pressure and heart rate and is highly selective for the tracheal muscle. It is indicated to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and emphysema. Serious side effects detected were: tremor, palpitations and serum potassium level decrease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 209 Target ID: CHEMBL210 Sources: http://www.mylan.co.jp/-/media/MylanJP/documents/epd_products/interview_updated/if_hokunalin.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15212190	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8583	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981
Bronchitis 51 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1078	Palliative	Approved 8583	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981
Chronic obstructive pulmonary disease 175 Sources: http://hokunalin.jp/patient/introduction/effect.html	Palliative	Approved 8583	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, COPD or emphysema. Launch Date 1981
Emphysema 13 Sources: http://www.mylan.co.jp/-/media/mylanjp/documents/epd_products/20170220%20hokunalin1ds0.1_r7.pdf	Palliative	Approved 8583	Hokunalin Approved Use It is usually used to improve symptoms such as respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema. Launch Date 1981

C_max

Value	Dose	Analyte	Population
6 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=27	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status:
4.46 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=28	20 μg/kg bw single, oral dose: 20 μg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL blood	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FASTED
0.48 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=20	0.5 mg single, topical dose: 0.5 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.59 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=21	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.29 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=22	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	600 μg single, respiratory dose: 600 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	4 mg single, topical dose: 4 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	6 mg single, topical dose: 6 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
30.5 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=27	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status:
10.75 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=20	0.5 mg single, topical dose: 0.5 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.09 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=21	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
27.62 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=22	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	600 μg single, respiratory dose: 600 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
53.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	4 mg single, topical dose: 4 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
82.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	6 mg single, topical dose: 6 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
3.19 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=27	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status:
3.56 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=28	20 μg/kg bw single, oral dose: 20 μg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL blood	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: FASTED
11.1 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=20	0.5 mg single, topical dose: 0.5 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=21	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/780075_2259707S1110_1_007_1F.pdf#page=22	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	600 μg single, respiratory dose: 600 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	2 mg single, topical dose: 2 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	4 mg single, topical dose: 4 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	6 mg single, topical dose: 6 mg route of administration: Topical experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8099880/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TULOBUTEROL serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
71.86% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/430920_2259002F1090_2_10A_1F.pdf#page=29			TULOBUTEROL serum	Homo sapiens

Doses

Dose	Population	Adverse events
1 mg 2 times / day multiple, oral Recommended Dose: 1 mg, 2 times / day Route: oral Route: multiple Dose: 1 mg, 2 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977	Disc. AE: Serum potassium decreased... AEs leading to discontinuation/dose reduction: Serum potassium decreased Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977
2 mg 1 times / day multiple, transdermal Recommended Dose: 2 mg, 1 times / day Route: transdermal Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18344636/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/18344636/	Sources: https://pubmed.ncbi.nlm.nih.gov/18344636/
400 ug 4 times / day multiple, respiratory Studied dose Dose: 400 ug, 4 times / day Route: respiratory Route: multiple Dose: 400 ug, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1974678/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1974678/	Sources: https://pubmed.ncbi.nlm.nih.gov/1974678/
2 mg 1 times / day multiple, transdermal Recommended Dose: 2 mg, 1 times / day Route: transdermal Route: multiple Dose: 2 mg, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505	Disc. AE: Anaphylaxis, Serum potassium decreased... AEs leading to discontinuation/dose reduction: Anaphylaxis Serum potassium decreased Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505

AEs

AE	Significance	Dose	Population
Serum potassium decreased	Disc. AE	1 mg 2 times / day multiple, oral Recommended Dose: 1 mg, 2 times / day Route: oral Route: multiple Dose: 1 mg, 2 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977
Anaphylaxis	Disc. AE	2 mg 1 times / day multiple, transdermal Recommended Dose: 2 mg, 1 times / day Route: transdermal Route: multiple Dose: 2 mg, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505
Serum potassium decreased	Disc. AE	2 mg 1 times / day multiple, transdermal Recommended Dose: 2 mg, 1 times / day Route: transdermal Route: multiple Dose: 2 mg, 1 times / day Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505	unhealthy, CHILD\|ADOLESCENT\|ADULT Health Status: unhealthy Age Group: CHILD\|ADOLESCENT\|ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505

PubMed

Title	Date	PubMed
Effect of porous silica on sustained release behaviors of pH sensitive pluronic F127/poly(acrylic acid) hydrogels containing tulobuterol.	2010-10-15	20621457
[Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry].	2010-08	21261043
Characterization and release behaviors of porous PCL/Eudragit RS microcapsules containing tulobuterol.	2010-04-01	20034769
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010-04	20155493
Simultaneous determination of beta2-agonists in human urine by fast-gas chromatography/mass spectrometry: method validation and clinical application.	2010-04	19642085
Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.	2010-02	19875277
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.	2010	20930390
Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma.	2009-12	19700936
Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis.	2009-08	19638730
Chronic eosinophilic pneumonia: a case report and review of the literature.	2009-07-02	19830005
Detection of tulobuterol crystal in transdermal patches using terahertz pulsed spectroscopy and imaging.	2009-06	19618670
Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder.	2009-05	19470012
Chemical mapping of tulobuterol in transdermal tapes using microscopic laser Raman spectroscopy.	2009-03	19348338
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease.	2008-12	18983928
[Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry].	2008-11	19253549
Cough and transdermal long-acting beta2 agonist in Japan.	2008-10	18573645
Characterization of monolithic matrix patch system containing tulobuterol.	2008-08	18787793
Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline.	2008	18344636
Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.	2008	17632023
Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch.	2007-09	17587559
Bioequivalence of marketed transdermal delivery systems for tulobuterol.	2007-08	17666825
[Simultaneous determination of nine beta2-agonists residues in urines by ultra performance liquid chromatography-electrospray tandem mass spectrometry].	2007-07	17953220
Transdermal treatment with tulobuterol increases isometric contractile properties of diaphragm muscle in mice.	2007-07	17592218
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.	2007-03	17454319
[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients].	2007-01	17331388
Treatment with beta2-adrenoceptor agonist in vivo induces human clock gene, Per1, mRNA expression in peripheral blood.	2007	17364588
Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.	2007	17049894
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.	2006-11	17042908
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.	2006-09	16939989
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.	2006-06	16802779
Immunology and homeopathy. 3. Experimental studies on animal models.	2006-06	16786046
Differential effects of short-acting beta2-agonists on human granulocyte functions.	2006	16272820
Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry.	2005-03-12	15759727
Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry.	2005-03-12	15759725
High-performance liquid chromatography electrospray ionization mass spectrometry determination of tulobuterol in rabbit's plasma.	2005-02-07	15664761
Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.	2005	16336029
Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy.	2005	16021849
Evaluation of MISPE for the multi-residue extraction of beta-agonists from calves urine.	2004-05-05	15093162
[Patchs: the success of transdermal administration].	2004-04	15222181
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].	2004-02	15007912
Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma.	2004	15212190
[Pharmacological action and clinical aspects of salmeterol].	2003-09	12939544
Effects of a nitro compound patch on neuropathy in Churg-Strauss syndrome.	2003-07	12823139
Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function.	2002-12	12390295
[Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma].	2002-01	11828751
[Long-acting beta 2-stimulants].	2001-10	11676141
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].	2001-10	11676124
Quantitative determination of clenbuterol, salbutamol and tulobuterol enantiomers by capillary electrophoresis.	2001-02	11293696
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.	2001-01	11201164
Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol.	1987-12	2893778

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults and children aged 9 or older, apply 2 mg of the tape to the chest, back, or upper arm, once daily. For children aged 6 months to 2 years, apply 0.5 mg of the tape to the chest, back, or upper arm, once daily. For children aged 3 to 8 years, apply 1 mg of the tape to the chest, back, or upper arm, once daily. This preparation contains 2 mg of the active ingredients in a piece of tape.

Route of Administration: Transdermal

In Vitro Use Guide

The binding rate of 14 C-tulobuterol hydrochloride to the serum protein (human) was 28.14 ± 1.53% in vitro (Mean ± S.E.).

Name

Type

Language

ATENOS

Preferred Name

English

Tulobuterol hydrochloride

Common Name

English

HOKUNALIN

Brand Name

English

TULOBUTEROL HCL

Common Name

English

TULOBUTEROL HYDROCHLORIDE [MART.]

Common Name

English

BRELOMAX

Brand Name

English

.ALPHA.-((TERT-BUTYLAMINO)METHYL)-O-CHLOROBENZYL ALCOHOL HYDROCHLORIDE

Common Name

English

CHLIBAMOL

Brand Name

English

TULOBUTEROL HYDROCHLORIDE [JAN]

Common Name

English

RESPACAL

Brand Name

English

LOBUTEROL

Brand Name

English

BERACHIN

Brand Name

English

BREMAX

Brand Name

English

TULOBUTEROL HYDROCHLORIDE [MI]

Common Name

English

Tulobuterol hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

MERCK INDEX

m11261